Aktis Oncology Shares Surge Over 5% on First Trading Day
With the first biotech IPO of the year, Aktis Oncology blew past expectations, with shares jumping on the first day of trading.LATEST IPOS AND DIRECT LISTINGS:Aktis Oncologyopened on January 9 at $27. The clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations priced its upsized initial public offering of 17.65M shares of its common stock at a price to the public of $18.00 per share. The deal priced at the high-end of the $16.00-$18.00 range.Buda Juiceopened on January 8 at $12. The company priced its initial public offering of 2,666,667 shares of its common stock at the public offering price of $7.50 per share. The deal priced at the low end of its $7.50-$9.00 range. Buda Juice intends to use the net proceeds from the offering to develop and build production plants in South Carolina and Arizona/Nevada, expand capacity in its Dallas production plant, support in-store marketing and provide working capital for its expansion of its freshly crafted juices, lemonades, and wellness shots to grocery retailers.RECENT SPAC IPOS:Lafayette Digital Acquisition Iopened on January 9 at $10.01. The blank check company had priced its initial public offering of 25M units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-fourth of one redeemable warrant. Each whole warrant, which becomes exercisable 30 days after the completion of the company's initial business combination, will entitle the holder thereof to purchase one Class A ordinary share at $11.50 per share, subject to adjustments.Bleichroeder Acquisition IIopened on Jnauary 8 at $10.03. The blank check company may pursue an acquisition opportunity in any industry, sector or geographic region. The company's primary focus, however, will be on North American and European businesses in disruptive growth sectors, which may include companies within sectors that are being transformed via technology adoption.Soren Acquisitionopened on January 7 at $10. The blank check company may pursue an acquisition opportunity in any business or industry or at any stage of its corporate evolution, but is focused on completing a business combination with "an attractive target business within the healthcare industry".Black Spade Acquisition IIIopened on January 6 at $9.97. The special purpose acquisition company is sponsored by an affiliate of Black Spade Capital Limited.PERFORMANCE:Prices as of 11 am ET on Monday, January 12 -Aktis Oncology – up over 5% at $23.53;Buda Juice – up almost 2% at $8.31.RECENT IPOS TO WATCH:Medlineand Andersen Groupare already seeing coverage roll out, while Starfighters Spaceis among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include PicS N.V., Grayscale, Klook, Speed Group, and Lendbuzz.Clickto see upcoming IPO calendar on TipRanks.PicS N.V.filed for an initial public offering of Class A common shares, which it intends to apply to list on the Nasdaq Global Select Market under the symbol "PICS." The company said it will not seek a listing for its Class B common shares on Nasdaq or on any other exchange. The filing stated, "PicPay Netherlands, the company whose Class A common shares are being offered in this prospectus, was incorporated on December 27, 2023, as a private limited liability company under Dutch law, with its corporate seat in Amsterdam, the Netherlands, with the name 'Picpay Holdings Netherlands B.V.' Prior to the closing of this offering, the issuer will be converted into a public limited liability company under Dutch law with the name 'PicS N.V.'... At PicPay, we believe financial services should be mobile, frictionless, and instantaneous. Our mission is to empower consumers and businesses across Brazil with innovative solutions to redefine the way people manage their traditional daily finances. We break down the barriers to traditional financial services and are driven by a vision of a future where financial services are accessible for all. We are committed to simplifying financial transactions, fostering economic inclusion and providing the tools and resources for people to achieve their financial goals."GrayscaleInvestments filed a prospectus for an initial public offering on the New York Stock Exchange under the ticker symbol "GRAY." Grayscale says it is the largest digital asset-focused investment platform in the world, with $35B in assets under management as of September 30. "Our mission is to make digital asset investing simple and open to every investor. Founded in 2013, we have pioneered regulated access to the digital asset class. Our platform spans the full spectrum of institutional-grade solutions, providing investors with the broadest and most diverse suite of digital asset-focused investment products in the United States based on number of products," the company added.Klook Technology, which identifies itself as "the largest pan-regional experiences platform in Asia-Pacific" by gross transaction volume in 2024, announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of American Depositary Shares representing its ordinary shares. The company has applied to list the ADSs on the New York Stock Exchange under the ticker symbol "KLK". The number of ADSs to be offered and the price range for the proposed offering have not yet been determined.Speed Groupfiled a prospectus for 2.5M share initial public offering. It expects the IPO price to be in the range of $4.00 to $5.00 per. The company's operating subsidiary, Speed Logistics, is an e-commerce logistics provider providing end-to-end logistics solution in Hong Kong, Europe and North America. The services include warehousing, customs clearance, air transportation, and final delivery from the European airports. For the years ended June 30, 2024 and 2025, Speed's revenues were $17.9M and $22.64M, respectively.Lendbuzz Inc.is offering an undetermined number of shares of its common stock and the selling stockholders identified in this prospectus are offering additional shares of common stock, according to an initial public offering prospectus filed with the SEC. The company has applied to list its common stock on the Nasdaq Global Select Market under the symbol "LBZZ." The prospectus states: "Our mission is to offer fair access to credit for underserved populations. We are a financial technology company that utilizes artificial intelligence, or AI, and machine learning algorithms to better assess consumer credit risk and expand access to credit. We seamlessly process large sets of data through advanced computational approaches to more accurately predict a consumer's creditworthiness. Our business benefits both consumers through expanded access to credit, and auto dealerships via increased vehicle sales."OTHER IPO NEWS:Construction equipment rental firm EquipmentShare.com, which filed publicly for a listing on December 9, may begin formal marketing for its initial public offering as soon as next week and could raise about $1B, a person familiar with the matter told Bloomberg's Bailey Lipschultz and Anthony Hughes. Motive Technologies, which makes artificial intelligence-enabled fleet management software and filed its IPO paperwork publicly on December 23, may also begin formal marketing next week as it seeks to raise around $600M, the report noted that a person with knowledge of the deal said."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
Trade with 70% Backtested Accuracy
Analyst Views on MDLN

No data
About MDLN
About the author

- IPO Financing Scale: Medline's IPO successfully raised $6.3 billion at a price of $29 per share, significantly enhancing the company's capital structure, with plans to use the proceeds to pay down $16.5 billion in debt, thereby improving financial health.
- Sales Growth Momentum: Since its founding in 1966, Medline has achieved an average annual sales growth of 18%, with projections indicating sales will reach $30 billion by 2026, demonstrating strong growth potential in the medical supply market, particularly given the resilience of healthcare demand amid economic uncertainties.
- Market Competitive Advantage: With 335,000 products and 33 manufacturing facilities, Medline offers next-day delivery to 95% of U.S. customers, leveraging its private label products to enhance margins and solidify its leadership position in the medical product supply chain.
- Superior Financial Performance: Medline boasts a gross margin of approximately 27.4%, significantly higher than key competitors, and is projected to generate $1.5 billion in free cash flow in 2025, showcasing its profitability and cash flow generation capabilities, further enhancing its investment appeal.
- Successful IPO: Medline went public on December 17, 2025, at Nasdaq, marking the largest private equity-backed IPO in U.S. history by raising over $7 billion, demonstrating strong market demand for medical supplies.
- Stock Performance: Since its debut, Medline's stock has surged nearly 30%, reflecting investor confidence in its growth potential and providing a positive signal for future IPOs of private equity-backed companies.
- Private Equity Market Dynamics: The number of global private equity exits rose 5.4% last year to 3,149, yet the total deal value declined by 21.2% year-over-year to $412.1 billion, indicating pressure and recalibration within the industry amid high interest rates.
- Investor Confidence: Due to stalled exits over recent years, private equity fundraising declined by 11% in 2025 to $490.81 billion, leading limited partners to be cautious about reinvesting, reflecting concerns over future investment returns.
- Recovery of Deal Cycle: Blackstone's COO Jonathan Gray stated that the global deal cycle has hit 'escape velocity', with accelerating IPO and M&A activities indicating a market resurgence, particularly driven by rising investments tied to artificial intelligence.
- Surge in IPO Activity: According to Blackstone, global IPO issuance surged 40% year-over-year in the fourth quarter, with a staggering 2.5-fold increase in the U.S. market, reflecting strong demand from investors for new public offerings.
- Improved Liquidity: Gray noted that the return of exits is enhancing limited partner liquidity, as capital and gains return, making it easier for limited partners to allocate more capital to Blackstone, thereby reigniting the capital flywheel.
- Earnings Report Performance: Despite reporting fourth-quarter revenue of $3.94 billion, down 5% year-over-year, Blackstone's distributable earnings reached $2.2 billion, exceeding analyst expectations, showcasing the company's resilience in adversity, even as its stock fell by 2.62%.
- Rating Downgrade: Goldman Sachs analyst Katherine Murphy initiated coverage of Super Micro Computer (NASDAQ:SMCI) on January 13 with a Sell rating and a price target of $26, reflecting a pessimistic outlook that may lead to decreased investor confidence.
- Merger Approval: Shareholders of Huntington Bancshares (NASDAQ:HBAN) and Cadence Bank approved their pending merger on January 6, which is expected to enhance market competitiveness and resource integration, driving future business growth.
- Analyst Support: Multiple analysts initiated coverage of Medline Inc. (NASDAQ:MDLN) on January 12 with bullish ratings, indicating a positive market sentiment towards the company's prospects that could attract more investor interest.
- Market Reaction: Super Micro Computer's shares jumped 11.1% to settle at $32.66 on Friday, indicating mixed market reactions to Jim Cramer's sell recommendation, which may influence subsequent investment decisions.
- Super Micro Computer Rating: Analysts have rated Super Micro Computer as a sell, indicating concerns about its future performance, which could lead to decreased investor confidence and negatively impact its stock price.
- Alkermes Stock Recommendation: Alkermes has been rated as not recommended by analysts, reflecting skepticism about its growth potential, which may affect its ability to raise capital and overall market performance.
- Medline Investment Outlook: Medline is strongly recommended as a buy by analysts, who describe its stock performance as 'unbelievable', potentially attracting more investor interest and driving its stock price higher.
- STMicroelectronics Investment Advice: STMicroelectronics is viewed as cheap and performing well, with analysts suggesting a buy, which could attract value investors and enhance its market position.
- IPO Success: Medline closed its IPO in December 2025, raising over $7 billion by offering 248.44 million shares at $29 each, marking the largest IPO globally in 2025 and significantly enhancing its market position.
- Market Leadership: Analysts highlight Medline's leadership in the U.S. medical-surgical product manufacturing and distribution sector, projecting sustainable high-single-digit organic growth driven by market share gains and strong demand.
- Positive Analyst Ratings: Firms like Bank of America and BTIG initiated coverage with 'Buy' ratings and a price target of $50, indicating a 23% potential upside, reflecting strong market confidence in Medline's growth prospects.
- Enhanced Financial Flexibility: Post-IPO, Medline plans to pay down $4 billion in debt, leaving approximately $1 billion for potential M&A or international expansion, further solidifying its competitive edge in a $375 billion addressable market.











